A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...

Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide ...

In a phase 2 trial, an investigational drug that inhibits aldosterone synthase significantly lowered albuminuria in patients with or without type 2 diabetes. PHILADELPHIA—A novel selective aldosterone ...

An investigational antihypertensive agent that inhibits the enzyme involved in aldosterone production, called MLS-101, significantly reduces blood pressure in patients with uncontrolled and resistant ...

Please provide your email address to receive an email when new articles are posted on . Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of ...

A steroid hormone called aldosterone is linked to an increased risk of kidney failure in patients with chronic kidney disease (CKD), according to a study published in the European Heart Journal [1] ...

Higher serum aldosterone levels among patients with chronic kidney disease (CKD) are independently associated with an increased risk for CKD progression and end-stage kidney disease (ESKD) regardless ...

Aldosterone acts as a mediator of hypertension, heart failure and kidney disease, and aldosterone synthase inhibitors (ASIs) have emerged as an alternative approach for the treatment of some of these ...

Type 2 diabetes (T2D) incidence continues to rise among African Americans (AAs). However, it has been observed to plateau among non-Hispanic whites (NHWs). Moreover, T2D-associated mortality and ...

Please provide your email address to receive an email when new articles are posted on . Mineralocorticoid receptor antagonists, particularly the most recently approved agent finerenone, should play a ...